Bio-Rad Intends to Propose Three New Independent Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Bio-Rad Labs (BIO) PT Raised to $250 at Jefferies; Sees Path to $300
March 14, 2017 6:37 AM EDTJefferies raised its price target on Bio-Rad Labs (NYSE: BIO) to $250.00 (from $225.00) while maintaining a Buy rating. The analyst also sees a path to $300 share.
Analyst Brandon Couillard commented, "Time to forget everything you thought you knew about BIO -- as two separate... More
